| APOBEC3B is an enzymatic source of mutation in breast cancer MB Burns, L Lackey, MA Carpenter, A Rathore, AM Land, B Leonard, ... Nature 494 (7437), 366-370, 2013 | 884 | 2013 |
| APOBEC3B is an enzymatic source of mutation in breast cancer MB Burns, L Lackey, MA Carpenter, A Rathore, AM Land, B Leonard, ... Nature 494 (7437), 366-370, 2013 | 884 | 2013 |
| Effect of HIV antibody VRC01 on viral rebound after treatment interruption KJ Bar, MC Sneller, LJ Harrison, JS Justement, ET Overton, ME Petrone, ... New England Journal of Medicine 375 (21), 2037-2050, 2016 | 465 | 2016 |
| Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction EW Refsland, MD Stenglein, K Shindo, JS Albin, WL Brown, RS Harris Nucleic acids research 38 (13), 4274-4284, 2010 | 405 | 2010 |
| Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1 JF Hultquist, JA Lengyel, EW Refsland, RS LaRue, L Lackey, WL Brown, ... Journal of virology 85 (21), 11220-11234, 2011 | 398 | 2011 |
| Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1 JF Hultquist, JA Lengyel, EW Refsland, RS LaRue, L Lackey, WL Brown, ... Journal of virology 85 (21), 11220-11234, 2011 | 398 | 2011 |
| The APOBEC3 family of retroelement restriction factors EW Refsland, RS Harris Intrinsic immunity, 1-27, 2013 | 241 | 2013 |
| Quantitative proteomics reveals myosin and actin as promising saliva biomarkers for distinguishing pre-malignant and malignant oral lesions EP de Jong, H Xie, G Onsongo, MD Stone, XB Chen, JA Kooren, ... PloS one 5 (6), e11148, 2010 | 126 | 2010 |
| A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection MC Sneller, JS Justement, KR Gittens, ME Petrone, KE Clarridge, ... Science translational medicine 9 (419), eaan8848, 2017 | 118 | 2017 |
| Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n EW Refsland, JF Hultquist, RS Harris PLoS pathogens 8 (7), e1002800, 2012 | 117 | 2012 |
| Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity EW Refsland, JF Hultquist, EM Luengas, T Ikeda, NM Shaban, EK Law, ... PLoS genetics 10 (11), e1004761, 2014 | 110 | 2014 |
| Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals KE Clarridge, J Blazkova, K Einkauf, M Petrone, EW Refsland, ... PLoS pathogens 14 (1), e1006792, 2018 | 93 | 2018 |
| Interactions among DNA ligase I, the flap endonuclease and proliferating cell nuclear antigen in the expansion and contraction of CAG repeat tracts in yeast EW Refsland, DM Livingston Genetics 171 (3), 923-934, 2005 | 38 | 2005 |
| Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals J Blazkova, EW Refsland, KE Clarridge, V Shi, JS Justement, ED Huiting, ... The Journal of Clinical Investigation 129 (11), 4832-4837, 2019 | 12 | 2019 |
| Highlights from the Fourth Biennial Strategies for an HIV Cure Meeting, 10–12 October 2018, Bethesda, MD, USA L Kuo, D Lawrence, D McDonald, E Refsland, S Bridges, S Smiley, ... Journal of virus eradication 5 (1), 50-59, 2019 | 12* | 2019 |
| Effect of infusion of broadly neutralizing antibody VRC01 on HIV plasma rebound TW Chun, M Sneller, C Seamon, JS Justement, M Petrone, E Refsland, ... Conference on Retroviruses and Opportunistic Infections, 2016 | 7 | 2016 |
| Cancer biomarker, diagnostic methods, and assay reagents RS Harris, M Burns, EW Refsland US Patent App. 13/437,484, 2012 | 2 | 2012 |
| 536 Kotandeniya D, Tretyakova N, Nikas JB, Yee D, Temiz NA, Donohue DE, McDougle RM, 537 Brown WL, Law EK, Harris RS. 2013. APOBEC3B is an enzymatic source of mutation in … MB Burns, L Lackey, MA Carpenter, A Rathore, AM Land, B Leonard, ... Nature 494, 366-70, 0 | 2 | |
| Determination of the Endogenous HIV-Restrictive APOBEC3 Repertoire EW Refsland University of Minnesota, 2014 | | 2014 |
| Abstract LB-193: APOBEC3 catalyzed genomic mutations in breast cancer MB Burns, L Lackey, A Land, A Rathore, E Refsland, R Harris Cancer Research 71 (8_Supplement), LB-193-LB-193, 2011 | | 2011 |
